C4 Therapeutics, Inc. (CCCC)


+0.01 (+0.83%)
Symbol CCCC
Price $1.22
Beta 2.235
Volume Avg. 0.54M
Market Cap 60.123M
Shares () -
52 Week Range 1.06-9.41
1y Target Est -
DCF Unlevered CCCC DCF ->
DCF Levered CCCC LDCF ->
ROE -53.11% Strong Sell
ROA -39.93% Strong Sell
Operating Margin -
Debt / Equity 33.41% Neutral
P/E -0.44 Neutral
P/B 0.28 Neutral


Consensus EPS

Upgrades & Downgrades

Latest CCCC news

Mr. Andrew J. Hirsch M.B.A.
NASDAQ Global Select

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.